Pro Medicus's Bull Rebases Forecasts in Realism -- Market Talk

Dow Jones

Apr 20

0109 GMT - Pro Medicus keeps its bull at Morgans despite the broker shifting its valuation model to one that prioritizes achievability over optimism. Maintaining a buy rating on Australian imaging-tech provider, analyst Iain Wilkie says that he is simply rebasing expectations to levels he is confident it can meet or beat. He tells clients in a note that the new model is more sensitive to the timing of contract implementations and reflects a materially stronger Australian dollar. Wilkie says recent contract announcements have confirmed demand and pricing power. Morgans cuts its target price 24% to A$210.00. Shares are down 1.3% at A$146.74. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

April 19, 2026 21:09 ET (01:09 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2628792045"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2628792045\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2628792045?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-20 09:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2628792045","market":"us","top_or_hot":-1,"title":"Pro Medicus's Bull Rebases Forecasts in Realism -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0109 GMT - <a href=\"https://laohu8.com/S/PMCUF\">Pro Medicus</a> keeps its bull at Morgans despite the broker shifting its valuation model to one that prioritizes achievability over optimism. Maintaining a buy rating on Australian imaging-tech provider, analyst Iain Wilkie says that he is simply rebasing expectations to levels he is confident it can meet or beat. He tells clients in a note that the new model is more sensitive to the timing of contract implementations and reflects a materially stronger Australian dollar. Wilkie says recent contract announcements have confirmed demand and pricing power. Morgans cuts its target price 24% to A$210.00. Shares are down 1.3% at A$146.74. (stuart.condie@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 19, 2026 21:09 ET (01:09 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pro Medicus's Bull Rebases Forecasts in Realism -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPro Medicus's Bull Rebases Forecasts in Realism -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-20 09:09</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0109 GMT - <a href=\"https://laohu8.com/S/PMCUF\">Pro Medicus</a> keeps its bull at Morgans despite the broker shifting its valuation model to one that prioritizes achievability over optimism. Maintaining a buy rating on Australian imaging-tech provider, analyst Iain Wilkie says that he is simply rebasing expectations to levels he is confident it can meet or beat. He tells clients in a note that the new model is more sensitive to the timing of contract implementations and reflects a materially stronger Australian dollar. Wilkie says recent contract announcements have confirmed demand and pricing power. Morgans cuts its target price 24% to A$210.00. Shares are down 1.3% at A$146.74. (stuart.condie@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 19, 2026 21:09 ET (01:09 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PME.AU","symbol_name":"PRO MEDICUS LTD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2628792045","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2628792045","pubTimestamp":1776647340,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0109 GMT - Pro Medicus keeps its bull at Morgans despite the broker shifting its valuation model to one that prioritizes achievability over optimism. Maintaining a buy rating on Australian imaging-tech provider, analyst Iain Wilkie says that he is simply rebasing expectations to levels he is confident it can meet or beat. He tells clients in a note that the new model is more sensitive to the timing of contract implementations and reflects a materially stronger Australian dollar. Wilkie says recent contract announcements have confirmed demand and pricing power. Morgans cuts its target price 24% to A$210.00. Shares are down 1.3% at A$146.74. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PME.AU":"PRO MEDICUS LTD","BK7094":"医疗保健技术"},"translate_title":"Pro Medicus的牛市根据现实主义重新调整了预测——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PME.AU":0.9},"content_text":"0109 GMT - Pro Medicus keeps its bull at Morgans despite the broker shifting its valuation model to one that prioritizes achievability over optimism. Maintaining a buy rating on Australian imaging-tech provider, analyst Iain Wilkie says that he is simply rebasing expectations to levels he is confident it can meet or beat. He tells clients in a note that the new model is more sensitive to the timing of contract implementations and reflects a materially stronger Australian dollar. Wilkie says recent contract announcements have confirmed demand and pricing power. Morgans cuts its target price 24% to A$210.00. Shares are down 1.3% at A$146.74. (stuart.condie@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 19, 2026 21:09 ET (01:09 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}